JAMP GRANISETRON TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
13-01-2020
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
GRANISETRON (GRANISETRON HYDROCHLORIDE)
Tilgængelig fra:
JAMP PHARMA CORPORATION
ATC-kode:
A04AA02
INN (International Name):
GRANISETRON
Dosering:
1MG
Lægemiddelform:
TABLET
Sammensætning:
GRANISETRON (GRANISETRON HYDROCHLORIDE) 1MG
Indgivelsesvej:
ORAL
Enheder i pakken:
15G/50G
Recept type:
Prescription
Terapeutisk område:
5-HT3 RECEPTOR ANTAGONISTS
Produkt oversigt:
Active ingredient group (AIG) number: 0123183001; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2018-02-02
Produktets egenskaber
PRODUCT MONOGRAPH
Pr
JAMP Granisetron
Granisetron Hydrochloride Tablets
1 mg granisetron (as granisetron hydrochloride)
Manufacturer Standard
Antiemetic
(5-HT
3
receptor antagonist)
Jamp Pharma Corporation
1310 rue Nobel
Boucherville, Québec
Canada J4B 5H3
Submission Control No.: 234371
DATE OF REVISION:
January 13, 2020
JAMP Granisetron
Page 2 of 25
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
..................................................................................................3
WARNINGS AND PRECAUTIONS
.................................................................................4
ADVERSE REACTIONS
..................................................................................................6
DRUG INTERACTIONS
..................................................................................................9
DOSAGE AND
ADMINISTRATION................................................................................9
OVERDOSAGE
..............................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 10
STORAGE AND
STABILITY.........................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 13
PART II: SCIENTIFIC
INFORMATION............................................................................
14
PHARMACEUTICAL
INFORMATION..........................................................................
14
CLINICAL TRIALS
........................................................................................................
14
DETAILED PHARMACOLOGY
..........
Læs hele dokumentet
